Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026)

Xilio Therapeutics has disclosed Change in Receivables across 3 years of filings, most recently posting -$5.0 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $12.5 million (changed N/A YoY), and the FY2025 annual result was $5.0 million, changed N/A from the prior year.
• Change in Receivables came in at -$5.0 million for Q1 2026 at Xilio Therapeutics, up from -$12.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $30.0 million in Q1 2024 to a low of -$12.5 million in Q4 2025.
• The 3-year median for Change in Receivables is -$5.0 million (2026), against an average of $4.2 million.